Get the Stockscreener App
174.19
3.09%
5.22
Icon Plc stock is traded at $174.19, with a volume of 349.89K.
It is up +3.09% in the last 24 hours and up +1.01% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$168.97
Open:
$170.2
24h Volume:
349.89K
Relative Volume:
0.43
Market Cap:
$13.44B
Revenue:
$8.27B
Net Income/Loss:
$173.28M
P/E Ratio:
80.23
EPS:
2.1712
Net Cash Flow:
$785.90M
1W Performance:
+5.89%
1M Performance:
+1.01%
6M Performance:
+49.52%
1Y Performance:
-7.27%
1-Day Range:
$166.94
$174.49
1-Week Range:
$159.72
$170.32
52-Week Range:
$66.57
$203.91
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
174.19 | 13.44B | 8.27B | 173.28M | 785.90M | 2.1712 |
TMO
Thermo Fisher Scientific Inc
|
693.35 | 256.36B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
231.68 | 162.87B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
402.42 | 58.01B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
176.41 | 49.74B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
269.96 | 44.44B | 16.63B | 1.39B | 2.12B | 8.0674 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-30-26 | Resumed | UBS | Neutral |
| Jun-30-26 | Upgrade | Truist | Hold → Buy |
| Jun-25-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-18-26 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
BofA Securities Upgrades Icon PLC (ICLR) to Neutral, Lifts Price Target Amid Positive CRO Outlook - GuruFocus
ICON plc Stock 12‑Month Price Target Raised to $187.81, Implies 14% Upside - TradingView
Results arrive after market close October 27 for ICON (ICLR), with an earnings call October 28. - Stock Titan
ICON Schedules Third Quarter 2026 Earnings Conference Call - Business Wire
RBC Capital Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $185 - Moomoo
Is Icon PLC (ICLR) a Bargain After 3.9% Drop? GF Value Says Unde - GuruFocus
UBS Maintains Icon PLC(ICLR.US) With Hold Rating, Maintains Target Price $195 - Moomoo
Q4 2025 ICON PLC Earnings Call Transcript - gurufocus.com
Icon PLC (ICLR) Stock Down 4.8% -- Now Undervalued? GF Score: 94/100 - gurufocus.com
UBS Restarts Coverage of Icon PLC (ICLR) with Neutral Rating and $195 Price Target - gurufocus.com
A Look at Icon PLC (ICLR) After 6.1% Gain -- GF Value $205.79 vs Price $173.90 - GuruFocus
ICON Plc (ICLR) Rises as Investors Appear to Lean on Backlog, Guidance, and Recent Filings - Moomoo
ICON plc (ICLR) rises as investors appear to lean on backlog, guidance, and recent filings - Quiver Quantitative
ICON Public Limited Company’s (ICLR) Shrinking Moat Warranted an Early Departure - Currently.com
ICON Public Limited Company’s (ICLR) Shrinking Moat Warranted an Early Departure - Yahoo Finance Singapore
Hybrid Clinical Research Associate Job at ICON | Apply Online Here - BioTecNika
Icon PLC (ICLR) Stock Up 3.3% and Still Undervalued -- GF Score: 95/100 - GuruFocus
Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
Icon PLC (ICLR) Stock Down 3.3% -- Now Undervalued? GF Score: 96/100 - GuruFocus
ICON PLC Director Eugene McCague Exercises Stock Options and Sells Shares on September 17, 2026 - Kalkine Media
Citi Maintains Icon PLC(ICLR.US) With Hold Rating, Raises Target Price to $175 - Moomoo
S&P 500 Futures Rise in Premarket Trading; Xenon Pharmaceuticals, Icon PLC Lag - barrons.com
Icon (ICLR) insider sells 5,005 shares after exercising options - Stock Titan
Director at ICON (ICLR) unloads stock right after exercising options - Stock Titan
Director at ICON (NASDAQ: ICLR) exercises options, then sells 5,005 shares - Stock Titan
Icon (ICLR) Stock Forecast and Price Target 2026 $ICLR - MarketBeat
ICON PLC (NASDAQ: ICLR) director plans 569,625 stock sale - Stock Titan
ICON (NASDAQ: ICLR) director plans to sell thousands of shares in 2026 - Stock Titan
ICON plc Q2 2026 Earnings: EPS Narrowly Misses Estimate as Stock Edges LowerProduct Revenue Analysis - careplusvn.com
ICON plc (NASDAQ: ICLR) director plans $876K sale after $138K trade - Stock Titan
ICON plc Stock Price: ICLR Stock Chart, Market Cap & News Today - CoinGecko
A Look at Icon PLC (ICLR) After 3.9% Gain -- GF Value $207.68 vs Price $165.69 - GuruFocus
ICON PLC (NASDAQ: ICLR) Releases Unaudited Interim Financial Statements in September 9 Filing - Kalkine Media
ICON taps Anthropic and Microsoft as it puts clinical-trial agents into production - R&D World
Is Icon PLC (ICLR) a Bargain After 4.1% Drop? GF Value Says Unde - GuruFocus
ICON plc (ICLR) Stock Report: Evaluating a 12.56% Potential Upside Amidst Healthcare Sector Expansion - DirectorsTalk Interviews
CVS Health (CVS) Up 1% Since Last Earnings Report: Can It Continue? - Zacks Investment Research
Long term debt to total equity ratio of ICON Plc – HAM:IJF - TradingView
Icon plc stock holds steady as Q2 2026 results support full-year guidance - ad-hoc-news.de
ICON Plc (ICLR) Stock Analysis: Exploring Growth Potential With A 9.14% Upside - DirectorsTalk Interviews
ICON plcADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
How ICON’s Mixed Q1 Earnings and Reaffirmed 2026 Outlook Could Impact ICON (ICLR) Investors - sahmcapital.com
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
ICON plcADR Key Financial Ratios – Valuation, Profitability & More - Value Research
ICON plcADR Peer Comparison – Compare with Others - Value Research
ICON plc (ICLR) Stock Analysis: Navigating Growth in Diagnostics & Research with a 7.74% Upside - DirectorsTalk Interviews
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability - BioSpace
ICON plc (ICLR) posts top-1% ESG score and 73% emissions cut - Stock Titan
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability - Business Wire
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability - Yahoo Finance
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Icon Plc Stock (ICLR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCague Eugene Pacelli | Director |
Sep 17 '26 |
Option Exercise |
125.74 |
3,255 |
409,284 |
7,066 |
| McCague Eugene Pacelli | Director |
Sep 17 '26 |
Sale |
175.00 |
3,255 |
569,625 |
3,811 |
| Murphy Ronan Martin | Director |
Sep 17 '26 |
Option Exercise |
125.74 |
5,005 |
629,329 |
8,852 |
| Murphy Ronan Martin | Director |
Sep 17 '26 |
Sale |
175.00 |
5,005 |
875,875 |
3,847 |
| EUGENE PACELLI MCCAGUE | Director |
Sep 17 '26 |
Proposed Sale |
175.00 |
3,255 |
569,625 |
0 |
| RONAN MARTIN MURPHY | Director |
Sep 17 '26 |
Proposed Sale |
175.00 |
5,005 |
875,875 |
0 |
| JOHN CLIMAX | Director |
Sep 16 '26 |
Proposed Sale |
175.00 |
5,005 |
875,875 |
0 |
| CLIMAX JOHN DR | Director |
Sep 16 '26 |
Sale |
175.00 |
5,005 |
875,875 |
2,087 |
| ANNE WHITAKER | Director |
Aug 11 '26 |
Proposed Sale |
164.29 |
841 |
138,170 |
0 |
| LINDA SUE GRAIS | Director |
Aug 11 '26 |
Proposed Sale |
164.29 |
841 |
138,170 |
0 |
1.76%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):